Skip to content
i2E
  • Programs
    • E3
    • ACT Tulsa
    • Love’s Entrepreneur’s Cup
    • OKBio
  • Client Portfolio
  • Services
    • Access to Funding
    • Venture Advisory Services
  • About
    • Our Values
    • Meet Our Team
    • Board of Directors
    • Corporate Partners
  • Contact
  • Media
Menu
  • Programs
    • E3
    • ACT Tulsa
    • Love’s Entrepreneur’s Cup
    • OKBio
  • Client Portfolio
  • Services
    • Access to Funding
    • Venture Advisory Services
  • About
    • Our Values
    • Meet Our Team
    • Board of Directors
    • Corporate Partners
  • Contact
  • Media
Search

Kirrhos Pharmaceuticals

Get in Touch

Oklahoma-based Kirrhos Pharmaceuticals is developing a novel, first-in-class treatment
for a severe form of non-alcoholic fatty liver disease known as NASH

OKLAHOMA CITY — i2E, Inc., recently led an $850,000 seed investment in Oklahoma
City-based Kirrhos Pharmaceuticals, which is developing a therapeutic for NASH, a life-
threatening liver condition that afflicts up to 12 percent of adult Americans.

NASH — nonalcoholic steatohepatitis – is associated with a spectrum of diseases
centered around the liver, said David Martin, PharmD, Kirrhos Pharmaceuticals chief
executive officer. It is termed a “modern lifestyle disease” by the NASH Education
Program, a collaborative initiative by stakeholders in NASH research and treatment.

“It’s basically a lifestyle disease, brought on primarily by a high-fat diet,” Martin said.
“People that are at high risk for it are people who are overweight, may or may not have
diabetes or are prone to diabetes and have a generally poor diet.”

The investment into Kirrhos Pharmaceuticals includes $425,000 from the i2E-managed
Oklahoma Accelerate Fund, along with matching investment from Angel investors.

The seed investment will allow Kirrhos to conduct preclinical proof-of-concept research
into its therapeutic, Martin said. A successful proof-of-concept would lead to a larger
Series A investment round that could carry to company into clinical trials, he said.

“NASH is a debilitating and potentially fatal disease with no approved therapeutic
treatment on the market,” said Carol Curtis, Ph.D., i2E Management Company vice
president and director of investments. “If Kirrhos is successful, it will bring relief to
millions of patients in the U.S. and worldwide.”

Kirrhos is the first spinout from Oklahoma City-based Ascend BioVentures, a
pharmaceutical accelerator formed in 2018 as a subsidiary of i2E in partnership with the
University of Oklahoma, the Oklahoma Medical Research Foundation (OMRF) and the
Presbyterian Health Foundation.

The Oklahoma Seed Capital Fund is a state-appropriated investment fund managed by
i2E through the Oklahoma Center for the Advancement of Science and Technology.

 

About Kirrhos Pharmaceuticals
Founded in early 2019, Kirrhos Pharmaceuticals is advancing a novel, “first-in-class”
therapeutic to treat a progressive non-alcoholic fatty liver disease known as NASH.

Author

  • katelynn katelynn

More News

Loading...
Black doctor smiling with stethoscope
Blog, i2E
02.09.23

Titan Intake Automates Patient Referrals to Accelerate Care

Read more
man and woman reviewing paperwork at a table
Blog, i2E, News
01.10.23

Stories of Oklahoma Innovation: Building a Startup

Read more
woman in lab conducting a study
Blog, i2E
12.13.22

Bayesic Technologies Improves Effectiveness and Efficiency of Data Analysis in Healthcare

Read more
Bison grazing fields
Blog
11.30.22

Bison Underground Merges Nature, Science, and Technology to Tackle Climate Change

Read more
African American family sitting on couch reading and chatting
Blog, E3, i2E
11.22.22

Fokes Connects Families, Caregivers and Care Agencies for Smoother Communications and Care 

Read more
i2e blog post graphic
Blog, News
11.03.22

Introducing: Stories of Oklahoma Innovation

Read more
Default Featured Image
OKBio
06.28.22

Oklahoma Grown! i2E Invests in BIO startups

Read more
Default Featured Image
OKBio
06.13.22

Oklahoma Medical Research Foundation BIO

Read more
Default Featured Image
OKBio
06.13.22

Moleculera Labs BIO

Read more
Default Featured Image
OKBio
06.13.22

University of Oklahoma Health Sciences Center BIO

Read more
Default Featured Image
OKBio
06.13.22

Oklahoma State University BIO

Read more
Default Featured Image
OKBio
06.13.22

ECHO Investment Capital BIO

Read more
i2E

Oklahoma City Office

840 Research Parkway, Suite 250
OKC, OK 73104
+1 (405) 235.2305

Tulsa Office

100 S. Cincinnati Ave – Suite 514
Tulsa, OK 74103
+1 (918) 582.5592

  • Client Portfolio
  • About Us
  • Media
  • Events
  • Contact
  • Resources

© 2022 i2E Privacy Policy

Follow us:

Facebook Twitter Linkedin

Programs

  • E3
  • ACT Tulsa
  • Love's Entrepreneur's Cup
  • OKBio
  • Client Portfolio

Services

  • Access to Funding
  • Venture Advisory Services
  • Contact
  • About
  • Our Values
  • Our Team
  • Board of Directors
  • Corporate Partners
  • Media
i2E